Sequential two-line strategy for stage IV non-small-cell lung cancer: Docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: Final results of a randomised phase II study

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 81-89

  Douillard, J Y ^a   Gervais, R ^b   Dabouis, G ^c   Le Groumellec, A ^d   D'Arlhac, M ^e   Spaeth, D ^f   Coudert, B ^g   Caillaud, D ^h   Monnier, A ⁱ   Clary, C ^j   Maury, B ^k   Mornet, M ^l   Riviere A ^b   Clouet, P ^m   Couteau, C ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b CENTRE FRANÇOIS BACLESSE   (France)

^c HÔTEL DIEU   (France)

^d CHG Chubert   (France)

^e Centre Hospitalier Georges Renon   (France)

^f CENTRE ALEXIS VAUTRIN   (France)

^g CENTRE GEORGES FRANÇOIS LECLERC   (France)

^h SERVICE DE RHUMATOLOGIE   (France)

ⁱ Service de Chirurgie Générale et Digestive   (France)

^j PASTEUR HOSPITAL   (France)

^k CHG   (France)

^l Hôpital J C ur   (France)

^m SANOFI   (France)

more..

Author keywords

Chemotherapy; Docetaxel; First line; Non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG PREFERENCE; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CROSS-OVER STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUTROPENIA; SURVIVAL ANALYSIS; TAXOIDS; VINBLASTINE;

EID: 19944427563     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi013     Document Type: Article

References (23)

1. Jemal A, Thomas A, Murray T et al. Cancer statistics 2002. CA Cancer J Clin 2002; 52: 23-47.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in NSCLC: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
3. Rapp E, Pater JL, William A et al. Chemotherapy can prolong survival with advanced non-small cell lung cancer. Report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-641.
4. Shepherd F, Ramlau R, Mattson K et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small-cell lung cancer previously treated with cisplatin based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
5. Fossella FV, De Vore R, Kerr R et al. Randomized phase III trial of docetaxel vs vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354-2362.
6. Rigas JR. Single agent docetaxel in previously untreated non small-cell lung cancer. Oncology 1997; 11 (Supp1 7): 17-21.
7. Fossella F, Pereira JR, Von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations vs vinorelbine plus cisplatin for advanced NSCLC: the TAX 326 study group. J Clin Oncol 2003; 16: 3016-3024.
8. Souquet PF, Cahuvin F, Boissel JP et al. Polychemotherapy in advanced NSCLC: a metaanalysis. Lancet 1993; 342: 19-21.
9. Sandler A, Nemunaitis J, Denham C et al. Phase III study of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-130.
10. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
11. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459-2465.
12. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin vs vinorelbine alone in advanced non-small cell lung cancer. Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
13. Le Chevalier T, Brisgand D, Soria JC et al. Prognostics analysis of survival in the European randomised trial comparing navelbine vs navelbine-cisplatin vs vindesine. Lung Cancer 2000; 29 (Suppl 2): 82a.
14. Kubota K, Watanabe K, Kunitoh H et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japonese Taxotere Lung Cancer Study Group. J Clin Oncol 2004; 22: 254-261.
15. Georgoulias V, Androulakis N, Dimopoulos AM et al. First line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 1998; 9: 331-334.
16. Le Chevalier T, Monnier A, Douillard JY et al. Docetaxel (Taxotere) plus cisplatin: an active and well tolerated combination in patients with advanced non-small cell cancer. Eur J Cancer 1998; 34: 2032-2036.
17. Zalcberg J, Millward M, Bishop J et al. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 1998; 16: 1948-1953.
18. Belani CP, Bonomi P, Dobbs T et al. Multicenter phase II study of docetaxel and cisplatin combination in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1997; 16: 221a (Abstr 37).
19. Comella P, Frasci G, Panza N et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine, in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000; 18: 1451-1457.
20. Kelly K, Crowley J, Bunn PA et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
21. Schiller JH, Harrington D, Belani C et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
22. Lilenbaum RC, Herndorn J, List C et al. Single agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomised trial of efficacy, quality of life and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21: (Abstr 2).
23. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicenter trial. Lancet 2001; 357: 1478-1484.